RAPP EBITDA | Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

Rapport Therapeutics, Inc. ebitda for the quarter ending 2026-06-30 was -$60.59M, a change of -$31.35M year-over-year.
Rapport Therapeutics, Inc. ebitda for the quarter ending 2026-03-31 was -$23.99M, a change of $2.88M year-over-year.
Rapport Therapeutics, Inc. ebitda for the quarter ending 2025-12-31 was -$38.24M, a change of -$14.98M year-over-year.
Rapport Therapeutics, Inc. ebitda for the quarter ending 2025-09-30 was -$29.73M, a change of -$8.31M year-over-year.
Rapport Therapeutics, Inc. ebitda for fiscal 2025 was -$124.08M, a change of -$41.87M from fiscal 2024.
Rapport Therapeutics, Inc. ebitda for fiscal 2024 was -$82.22M, a change of -$46.15M from fiscal 2023.
Rapport Therapeutics, Inc. ebitda for fiscal 2023 was -$36.07M.

Available history: 2023-09-30 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$60.59M	-$60.81M	$212,000.00	(m)	(m)	$78.00K*	-$41.45M*	(m)	$51.41M	$9.39M	(m)
2026-03-31	Reported	-$23.99M	-$24.22M	$227,000.00	(m)	-119.94%	$86.00K	-$13.06M	(m)	$32.72M	$11.50M	(m)
2025-12-31	Reported	-$38.24M	-$38.51M	$265,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$29.73M	-$29.99M	$256,000.00	(m)	(m)	$134.00K*	-$17.46M*	(m)	$22.28M	(m)	(m)
2025-06-30	Reported	-$29.24M	-$29.5M	$252,000.00	(m)	(m)	$22.00K*	-$25.07M*	(m)	$22.68M	$6.82M	(m)
2025-03-31	Reported	-$26.86M	-$27.11M	$244,000.00	(m)	(m)	$291.00K	-$20.24M	(m)	$19.57M	$7.54M	(m)
2024-12-31	Reported	-$23.26M	-$23.52M	$260,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$21.42M	-$21.64M	$219,000.00	(m)	(m)	$140.00K*	-$16.41M*	(m)	$15.54M	(m)	(m)
2024-06-30	Reported	-$20.59M	-$20.8M	$208,000.00	(m)	(m)	$967.00K*	-$16.35M*	(m)	$15.69M	(m)	(m)
2024-03-31	Reported	-$16.94M	-$17.09M	$152,000.00	(m)	(m)	$1.07M	-$17.61M	(m)	$12.50M	(m)	(m)
2023-12-31	Reported	-$14.74M	-$14.79M	$53,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$9.54M	-$9.56M	$23,000.00	(m)	(m)	$52.00K*	-$5.42M*	(m)	$7.58M	(m)	$1.00K
2023-06-30	Reported	(m)	-$6.63M	(m)	(m)	(m)	(m)	(m)	(m)	$4.72M	(m)	$2.00K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$124.08M	-$125.1M	$1.02M	(m)	(m)	$616.00K	-$87.47M	(m)	$94.79M	(m)	$0.00
2024-12-31	Reported	-$82.22M	-$83.06M	$839,000.00	(m)	(m)	$2.40M	-$64.83M	(m)	$60.94M	(m)	$0.00
2023-12-31	Reported	-$36.07M	-$36.18M	$112,000.00	(m)	(m)	$1.64M	-$27.18M	(m)	$28.00M	(m)	$10.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Stoke Therapeutics, Inc. (STOK)	United States	$1.630B	-9.82
Xeris Biopharma Holdings, Inc. (XERS)	United States	$1.632B	-80.10
Syndax Pharmaceuticals Inc (SNDX)	United States	$1.606B	-8.82
Kailera Therapeutics, Inc. (KLRA)	United States	$1.552B
ANAPTYSBIO, INC (ANAB)	United States	$1.546B	-60.20
Eton Pharmaceuticals, Inc. (ETON)	United States	$1.701B	80.74
Innoviva, Inc. (INVA)	United States	$1.493B	4.62
ArriVent BioPharma, Inc. (AVBP)	United States	$1.485B	-10.25
Xencor Inc (XNCR)	United States	$1.776B	-7.33
Septerna, Inc. (SEPN)	United States	$1.783B	-63.01